ArticleOncotarget2019

Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses.

Weng In Leong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.